Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease
University of Gothenburg · University of Warwick · +13 more institutions
Abstract
Abstract Patients with Alzheimer’s disease (AD) with little or no quantifiable insoluble brain tau neurofibrillary tangle (NFT) pathology demonstrate stronger clinical benefits of therapies than those with advanced NFTs. The formation of NFTs can be prevented by targeting the intermediate soluble tau assemblies (STAs). However, biochemical understanding and biomarkers of STAs are lacking. We show that Tris-buffered saline-soluble tau aggregates from autopsy-verified AD brain tissues include the core sequence ~tau 258–368 . In neuropathological assessments, antibodies against the phosphorylation sites serine-262 and serine-356 within the STA core almost exclusively stained granular (that is, prefibrillar) tau…
Citation impact
- FWCI
- 46.30
- Percentile
- 100%
- References
- 120
Authors
28- TITohidul IslamCorresponding
University of Gothenburg
- EHEmily Hill
University of Warwick
- EEEric E. Abrahamson
University of Pittsburgh, Geriatric Research Education and Clinical Center
- SSStijn Servaes
Montreal Neurological Institute and Hospital, McGill University
- DSDenis S. Smirnov
Brigham and Women's Hospital, University of California San Diego
Topics & keywords
- Tangle
- Serine
- Neurofibrillary tangle
- Disease
- Neuroscience
- Neurodegeneration
- Medicine
- Alzheimer's disease
- Good health and well-being
Funding
- AAAlzheimer's AssociationAwards: SG-23-1038904 QC, ADSF-21-831377-C, ZEN-21-848495, -21-850325, 21-831377-C, SG-23-1038904, 2021 Zenith Award, ADSF-21-831376-C, 850325, 34874, 33397, ADSF-21-831381-C, AARF-21-850325
- BABrigham and Women's Hospital
- MGMassachusetts General Hospital
- UOUniversity of Wisconsin-Madison
- FEFamiljen Erling-Perssons StiftelseAward: 860197
- UOUniversity of Pittsburgh
- MUMcGill UniversityAward: MOP-11-51-31
- FBFondation Brain CanadaAwards: 2020-VICO-279314, 34874, 33397
- WBWeston Brain Institute
- EJEU Joint Programme – Neurodegenerative Disease ResearchAwards: JPND2021-00694, JPND2019-466-236
- CCConsortium canadien en neurodégénérescence associée au vieillissement
- NINational Institute for Health and Care Research
- UOUniversity of Warwick
- UCUniversity College LondonAward: UKDRI-1003
- ECEuropean CommissionAwards: ALFGBG-71320, 860197, JPND2021-00694, 2022-2025, 101053962, JPND2019-466-236
- HHjärnfondenAwards: FO2017, ALFGBG-715986, JPND2019-466-236, ALFGBG-965240, FO2022-0270, ALZ2022-0006, FO2017-0243
- VVetenskapsrådetAwards: ALFGBG-965240, ALZ2022-0006, 2021-03244, 101053962, ALFGBG-715986, 2017-00915, 2022-01018, 2022-00732, 2019-02397, JPND2019-466-236, FO2017-0243, ALFGBG-71320
- SUSahlgrenska UniversitetssjukhusetAward: ALFGBG-71320
- GUGöteborgs Universitet
- UDUK Dementia Research InstituteAwards: UKDRI-1003, 2017-00915
- FPFondation pour la Recherche sur Alzheimer
- NINational Institutes of HealthAwards: P50AG005133, P01AG025204, P01AG14449, P30AG062429, RF1AG025516, RF1AG052525, P30AG066468, R01AG073267, R01AG072641, R01AG083874, R01AG053952, U24AG082930, R37AG023651, ZEN-21-848495, R01AG075336
- UOUniversity of California, San Diego
- SOSchool of Medicine and Public Health, University of Wisconsin-Madison
- GRGeriatric Research Education and Clinical Center
- HEHORIZON EUROPE Framework ProgrammeAwards: 101053962, 860197
- CICanadian Institutes of Health ResearchAwards: 201809, MOP-11-51-31, 2022-2025
- FDFonds de Recherche du Québec - SantéAward: 2020-VICO-279314
- SASahlgrenska Akademin
- NINational Institute on AgingAwards: P50AG005133, RF1AG025516, R01AG075336, P30AG062429, P01AG025204, P01AG14449, U24AG082930, R01AG072641, R37AG023651, R01AG053952, R01AG073267, P30AG066468
- NCNIH Clinical Center